Expression of Mfn2, the Charcot-Marie-Tooth neuropathy type 2A gene, in human skeletal muscle: Effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor α and interleukin-6

Diabetes

Volumn 54, Issue 9, 2005, Pages 2685-2693

  Bach, Daniel ^a   Naon, Deborah ^a   Pich, Sara ^a   Soriano, Francesc X ^a   Vega, Nathalie ^b   Rieusset, Jennifer ^b   Laville, Martine ^b   Guillet, Christelle ^c   Boirie, Yves ^c   Wallberg Henriksson, Harriet ^d   Manco, Melania ^e   Calvani, Menotti ^e   Castagneto, Marco ^e   Palacín, Manuel ^a   Mingrone, Geltrude ^e   Zierath, Juleen R ^d   Vidal, Hubert ^b   Zorzano, Antonio ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSERM   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d KAROLINSKA INSTITUTE   (Sweden)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; INTERLEUKIN 6; MESSENGER RNA; MITOFUSIN 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILIOPANCREATIC BYPASS; BODY MASS; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MFN2 GENE; MITOCHONDRIAL RESPIRATION; MORBID OBESITY; MUSCLE METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; WEIGHT REDUCTION;

CHARCOT-MARIE-TOOTH DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; INSULIN; INTERLEUKIN-6; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MITOCHONDRIAL PROTEINS; MUSCLE, SKELETAL; OBESITY; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT LOSS;

EID: 24144462451     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.9.2685     Document Type: Article

References (68)

1. Kelley DE, Simoneau JA: Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. J Clin Invest 94:2349-2356, 1994
2. Blaak EE, Wagenmakers AJ, Glatz JF, Wolffenbuttel BH, Kemerink GJ, Langenberg CJ, Heidendal GA, Saris WH: Plasma FFA utilization and fatty acid-binding protein content are diminished in type 2 diabetic muscle. Am J Physiol Endocrinol Metab 279:E146-E154, 2000
3. Sreekumar R, Halvatsiotis P, Schimke JC, Nair KS: Gene expression profile in skeletal muscle of type 2 diabetes and the effect of insulin treatment. Diabetes 51:1913-1920, 2002
4. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267-273, 2003
5. Berger M, Hagg SA, Goodman MN, Ruderman NB: Glucose metabolism in perfused skeletal muscle: effects of starvation, diabetes, fatty acids, acetoacetate, insulin and exercise on glucose uptake and disposition. Biochem J 158:191-202, 1976
6. Hagg SA, Taylor SI, Ruberman NB: Glucose metabolism in perfused skeletal muscle: pyruvate dehydrogenase activity in starvation, diabetes and exercise. Biochem J 158:203-210, 1976
7. Fuller SJ, Randle PJ: Reversible phosphorylation of pyruvate dehydrogenase in rat skeletal-muscle mitochondria: effects of starvation and diabetes. Biochem J 219:635-646, 1984
8. Yechoor VK, Patti ME, Saccone R, Kahn CR: Coordinated patterns of gene expression for substrate and energy metabolism in skeletal muscle of diabetic mice. Proc Natl Acad Sci U S A 99:10587-10592, 2002
9. Kelley DE, He J, Menshikova EV, Ritov VB: Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51:2944-2950, 2002
10. Savabi F, Kirsch A: Alteration of the phosphocreatine energy shuttle components in diabetic rat heart. J Mol Cell Cardiol 23:1323-1333, 1991
11. Gross MD, Harris S, Beyer RE: The effect of streptozotocin-induced diabetes on oxidative phosphorylation and related reactions in skeletal muscle mitochondria. Horm Metab Res 4:1-7, 1972
12. Astrup A, Andersen T, Henriksen O, Christensen NJ, Bulow J, Madsen J, Quaade F: Impaired glucose-induced thermogenesis in skeletal muscle in obesity: the role of the sympathoadrenal system. Int J Obes 11:51-66, 1987
13. Kelley DE, Mandarino LJ: Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 49:677-683, 2000
14. Cuendet GS, Loten EG, Jeanrenaud B, Renold AE: Decreased basal, noninsulin-stimulated glucose uptake and metabolism by skeletal soleus muscle isolated from obese-hyperglycemic (ob/ob) mice. J Clin Invest 58:1078-1088, 1976
15. Kemmer FW, Berger M, Herberg L, Gries FA, Wirdeier A, Becker K: Glucose metabolism in perfused skeletal muscle: demonstration of insulin resistance in the obese Zucker rat. Biochem J 178:733-741, 1979
16. Crettaz M, Prentki M, Zaninetti D, Jeanrenaud B: Insulin resistance in soleus muscle from obese Zucker rats: involvement of several defective sites. Biochem J 186:525-534, 1980
17. Kaplan ML, Oh SS: Oxygen consumption of muscles from ob/ob and Ay/a strains of obese mice. Int J Obes 15:809-812, 1991
18. Turcotte LP, Swenberger JR, Zavitz, TM, Yee AJ: Increased fatty acid uptake and altered fatty acid metabolism in insulin-resistant muscle of obese Zucker rats. Diabetes 50:1389-1396, 2001
19. Wardlaw GM, Kaplan ML, Lanza-Jacoby S: Effect of treadmill training on muscle oxidative capacity and accretion in young male obese and non-obese Zucker rats. J Nutr 116:1841-1852, 1986
20. Torgan CE, Brozinick JT Jr, Kastello GM, Ivy JL: Muscle morphological and biochemical adaptations to training in obese Zucker rats. J Appl Physiol 67:1807-1813, 1989
21. Amessou M, Fouque F, Soussi N, Desbuquois B, Hainaut I, Girard J, Benelli C: Longitudinal study of tissue- and subunit-specific obesity-induced regulation of the pyruvate dehydrogenase complex. Mol Cell Endocrinol 144:139-147, 1998
22. Ozaki K, Matsuura T, Narama I: Histochemical and morphometrical analysis of skeletal muscle in spontaneous diabetic WBN/Kob rat. Acta Neuropathol (Berl) 102:264-270, 2001
23. Bach D, Pich S, Soriano FX, Vega N, Baumgartner B, Oriola J, Daugaard JR, Lloberas J, Camps M, Zierath JR, Rabasa-Lhoret R, Wallberg-Henriksson H, Laville M, Palacin M, Vidal H, Rivera F, Brand M, Zorzano A: Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism: a novel regulatory mechanism altered in obesity. J Biol Chem 278:17190-17197, 2003
24. Santel A, Fuller MT: Control of mitochondrial morphology by a human mitofusin. J Cell Sci 114:867-874, 2001
25. Rojo M, Legros F, Chateau D, Lombes A: Membrane topology and mitochondrial targeting of mitofusins, ubiquitous mammalian homologs of the transmembrane GTPase Fzo. J Cell Sci 115:1663-1674, 2002
26. Hales KG, Fuller MT: Developmentally regulated mitochondrial fusion mediated by a conserved, novel, predicted GTPase. Cell 90:121-129, 1997
27. Rapaport D, Brunner M, Neuper W, Westermann B: Fzo1p is a mitochondrial outer membrane protein essential for the biogenesis of functional mitochondria in Saccharomyces cerevisiae. J Biol Chem 273:20150-20155, 1998
28. Pich S, Bach D, Briones P, Liesa M., Camps M., Testar X., Palacín M., Zorzano A: The Charcot-Marie-Tooth type 2A product, Mfn2, upregulates fuel oxidation through expression of OXPHOS system. Hum Mol Genet. In press
29. Zuchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, Zappia M, Nells E, Patitucci A, Senderek J, Parman Y, Evgrafov O, Jonghe PD, Takahashi Y, Tsuji S, Pericak-Vance MA, Quattrone A, Battaloglu E, Polyakov AV, Timmerman V, Schroder JM, Vance JM, Battologlu E: Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 36:449-451, 2004
30. Chen KH, Guo X, Ma D, Guo Y, Li Q, Yang D, Li P, Qiu X, Wen S, Xiao RP, Tang J: Dysregulation of HSG triggers vascular proliferative disorders. Nat Cell Biol 6:872-883, 2004
31. Andreelli F, Laville M, Ducluzeau PH, Vega N, Vallier P, Khalfallah Y, Riou JP, Vidal H: Defective regulation of phosphatidylinositol-3-kinase gene expression in skeletal muscle and adipose tissue of non-insulin-dependent diabetes mellitus patients. Diabetologia 42:358-364, 1999
32. Laville M, Rigalleau V, Riou JP, Beylot M: Respective role of plasma nonesterified fatty acid oxidation and total lipid oxidation in lipid-induced insulin resistance. Metabolism 44:639-644, 1995
33. Laville M, Auboeuf D, Khalfallah Y, Vega N, Riou JP, Vidal H: Acute regulation by insulin of phosphatidylinositol-3-kinase, Rad, Glut 4, and lipoprotein lipase mRNA levels in human muscle. J Clin Invest 98:43-49, 1996
34. Krook A, Roth RA, Jiang XJ, Zierath JR, Wallberg-Henriksson H: Insulin-stimulated Akt kinase activity is reduced in skeletal muscle from NIDDM subjects. Diabetes 47:1281-1286, 1998
35. Storgaard H, Song XM, Jensen CB, Madsbad S, Bjornholm M, Vaag A, Zierath JR: Insulin signal transduction in skeletal muscle from glucose-intolerant relatives of type 2 diabetic patients [corrected]. Diabetes 50:2770-2778, 2001
36. Calvani M, Scarfone A, Granato L, Mora EV, Nanni G, Castagneto M, Greco AV, Manco M, Mingrone G: Restoration of adiponectin pulsatility in severely obese subjects after weight loss. Diabetes 53:939-947, 2004
37. Lequerica JL, Mirabel V, Montero JA, Hurtado C, Piquer S, Carbonell F: In vitro proliferation, differentiation and immuno-magnetic bead purification of human myoblasts. Ann Transplant 4:103-108, 1999
38. Walsh FS, Ritter MA: Surface antigen differentiation during human myogenesis in culture. Nature 289:60-64, 1981
39. Rieusset J, Bouzakri K, Chevillotte E, Ricard N, Jacquet D, Bastard JP, Laville M, Vidal H: Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 53:2232-2241, 2004
40. Auboeuf D, Vidal H: The use of the reverse transcription-competitive polymerase chain reaction to investigate the in vivo regulation of gene expression in small tissue samples. Anal Biochem 245:141-148, 1997
41. Simoneau JA, Veerkamp JH, Turcotte LP, Kelley DE: Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss. FASEB J 13:2051-2060, 1999
42. Chang MY, Won SJ, Yang BC, Jan MS, Liu HS: Selective activation of Ha-ras(vall2) oncogene increases susceptibilityof NIH/3T3 cells to TNF-alpha. Exp Cell Res 248:589-598, 1999
43. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC: Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol 160:189-200, 2003
44. Binnert C, Koistinen HA, Martin G, Andreelli F, Ebeling P, Koivisto VA, Laville M, Auwerx J, Vidal H: Fatty acid transport protein-1 mRNA expression in skeletal muscle and in adipose tissue in humans. Am J Physiol Endocrinol Metab 279:E1072-E1079, 2000
45. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI: Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300:1140-1142, 2003
46. Hotamisligil GS: The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 245:621-625, 1999
47. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM: Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: central role of tumor necrosis factor-alpha. J Clin Invest 94:1543-1549, 1994
48. Hamann A, Benecke H, Marchand-Brustel Y, Susulic VS, Lowell BB, Flier JS: Characterization of insulin resistance and NIDDM in transgenic mice with reduced brown fat. Diabetes 44:1266-1273, 1995
49. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665-668, 1996
50. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87-91, 1993
51. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95:2409-2415, 1995
52. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA: The expression of TNF alpha by human muscle: relationship to insulin resistance. J Clin Invest 97:1111-1116, 1996
53. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334, 2001
54. Pickup JC, Chusney GD, Thomas SM, Burt D: Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 67:291-300, 2000
55. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA: Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52:2784-2789, 2003
56. Bruce CR, Dyck DJ: Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 287:E616-E621, 2004
57. Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, Kim JK: Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060-1067, 2004
58. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA: Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278:13740-13746, 2003
59. Stith RD, Luo J: Endocrine and carbohydrate responses to interleukin-6 in vivo. Circ Shock 44:210-215, 1994
60. Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP: Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 82:4167-4170, 1997
61. Pedersen BK, Steensberg A, Schjerling P: Muscle-derived interleukin-6: possible biological effects. J Physiol 536:329-337, 2001
62. Febbraio MA, Pedersen BK: Muscle-derived interleulkin-6: mechanisms for activation and possible biological roles. FASEB J 16:1335-1347, 2002
63. Steensberg A, Keller C, Starkie RL, Osada T, Febbraio MA, Pedersen BK: IL-6 and TNF-alpha expression in, and release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab 283:E1272-E1278, 2002
64. Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK: Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53:1643-1648, 2004
65. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP: Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 106:847-856, 2000
66. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM: A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92:829-839, 1998
67. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC, Spiegelman BM: Mechanisms, controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98:115-124, 1999
68. Parti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R, Landaker EJ, Goldfine AB, Mun E, DeFronzo R, Finlayson J, Kahn CR, Mandarino LJ: Coordinated reduction of genes of oxidative metabolism in humans with Insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 100:8466-8471, 2003